Drawing upon both molecular and histological evidence, BC may be systematically categorized into three primary subtypes: hormone receptor-positive BC (estrogen receptor (ER+) or progesterone receptor (PR+)), human epidermal receptor 2-positive BC (HER2+), and triple-negative breast cancer (TNBC)6–8. This evidence concerns the gene PGR and triple-negative breast carcinoma.